News Sentiment

ACRS sentiment intelligence

Aclaris Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.58 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+0.4% over one week, +29.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Vitiligo Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Dermira, Amgen, Pfizer, Dermavant Sciences, Incyte, TWi Biotechnology, Aclaris

Market Reaction

Balanced read

54/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction 0.4% Price digesting
Trend fit Trend active 29.2% over four weeks
Fair value 107.3% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 38
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 14
Market source 9
TradingKey 5
simplywall.st 5
Stock Titan 3
marketscreener.com 2
Moomoo 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 23
Analyst action 4
Regulatory and legal 2
Capital return 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
Barchart.com Direct company coverage

Vitiligo Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Dermira, Amgen, Pfizer, Dermavant Sciences, Incyte, TWi Biotechnology, Aclaris

DelveInsight's report details the Vitiligo pipeline for 2026, highlighting over 20 companies developing more than 25 treatment therapies. The report covers clinical development phases from pre-clinical to marketed stages, including recent clinical trial advancements and FDA appro

Tone
Positive 65/100
Event
Regulatory and legal
Published
07 Jul 2026 22:11
Source
Barchart.com
marketscreener.com Direct company coverage

Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 2500 Growth Benchmark

Aclaris Therapeutics, Inc. (NasdaqGS: ACRS) has been included in the Russell 2500 Growth Benchmark. This addition highlights the company's growth trajectory and increased visibility within the financial markets. The article also provides recent news and a company profile, detaili

Tone
Positive 90/100
Event
Market update
Published
29 Jun 2026 19:28
Source
marketscreener.com
TradingView Direct company coverage

ACRS Forecast — Price Target — Prediction for 2027

This article provides a forecast, price target, and prediction for Aclaris Therapeutics, Inc. (ACRS) stock. It includes analyst ratings, historical price data, financial metrics such as EPS, revenue, net income, and EBITDA, along with future earnings and revenue estimates. Invest

Tone
Positive 70/100
Event
Earnings
Published
29 Jun 2026 00:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS

This article provides the "Price to sales forward" metric for Aclaris Therapeutics, Inc. (NASDAQ: ACRS). The content outlines the company's financial data, accessible through TradingView, a platform offering various financial tools and market data for investors.

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 09:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Aclaris Therapeutics, Inc. – DUS:8AT

This article provides financial information for Aclaris Therapeutics, Inc. (DUS:8AT) on TradingView, specifically focusing on its enterprise value to EBIT forward metric. The content indicates that for the period, the value, change, and percentage change were "No trades." The inf

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 07:10
Source
TradingView
TradingView Direct company coverage

Price to book forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS

This article provides a brief mention of the "Price to book forward" metric for Aclaris Therapeutics, Inc. (NASDAQ: ACRS). It is presented within the context of financial data available on TradingView, indicating that the value for this metric is displayed alongside a change and

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 00:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Aclaris Therapeutics, Inc. – DUS:8AT

This page provides financial information for Aclaris Therapeutics, Inc. (8AT) on the Dusseldorf Stock Exchange, specifically focusing on its forward price-to-earnings ratio. The content indicates that the market is currently closed with no trades.

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 19:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS

This article provides the enterprise value to EBITDA forward for Aclaris Therapeutics, Inc. (NASDAQ: ACRS). It briefly details the company's stock information and acknowledges that market data is provided by ICE Data Services and FactSet. The content is primarily a data point wit

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 04:11
Source
TradingView
TradingView Direct company coverage

Aclaris Therapeutics, Inc. Actuals & Estimates (NASDAQ:ACRS)

This article provides an overview of Aclaris Therapeutics, Inc. (NASDAQ: ACRS), detailing its current stock price, historical performance, analyst forecasts, and key financial metrics. It also includes information on the company's market capitalization, earnings reports, revenue,

Tone
Positive 71/100
Event
Earnings
Published
26 Jun 2026 20:10
Source
TradingView
www.marketscreener.com Direct company coverage

Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to S&P Pharmaceuticals Select Industry Index

Aclaris Therapeutics, Inc. (NasdaqGS:ACRS) has been added to the S&P Pharmaceuticals Select Industry Index. The company is a clinical-stage biopharmaceutical firm focused on developing product candidates for immuno-inflammatory diseases, utilizing its proprietary KINect drug disc

Tone
Positive 76/100
Event
Market update
Published
21 Jun 2026 21:27
Source
www.marketscreener.com
TradingKey Direct company coverage

Aclaris Therapeutics Inc (ACRS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Aclaris Therapeutics Inc (ACRS) on TradingKey. It indicates that ACRS has distributed $0.00 in dividends over the past five years and has no recorded stock split data. The page also displays current stock p

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 08:40
Source
TradingKey
TradingKey Direct company coverage

Aclaris Therapeutics Inc (ACRS) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Aclaris Therapeutics Inc (ACRS), highlighting its current valuation score of 7.88 and its ranking within the Biotechnology & Medical Research industry. It notes the company's P/E ratio of -8.03, which is significantly below its recen

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 03:39
Source
TradingKey
TradingKey Direct company coverage

Aclaris Therapeutics Inc (ACRS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Aclaris Therapeutics Inc (ACRS), outlining both major individual shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and a list of active

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 01:39
Source
TradingKey
TradingKey Direct company coverage

Aclaris Therapeutics Inc (ACRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Aclaris Therapeutics Inc (ACRS), focusing on its business segments. As of April 6, the company's revenue is primarily derived from Licensing (76.08%, $5.95M) and Laboratory Research Revenue (23.92%, $1.87M). The report indica

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 00:39
Source
TradingKey
TradingKey Direct company coverage

Aclaris Therapeutics Inc (ACRS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Aclaris Therapeutics Inc (ACRS) has an earnings forecast score of 8.91, ranking 36th in its industry, with an average analyst price target of $7.00. Analysts largely recommend a "Buy" for ACRS stock, with a projected upside of over 110%. The company's expected revenue for the nex

Tone
Positive 72/100
Event
Earnings
Published
17 Jun 2026 17:39
Source
TradingKey
Finviz Direct company coverage

ACRS - Aclaris Therapeutics Inc Stock Price and Quote

This article provides comprehensive financial data, stock performance metrics, analyst ratings, and recent news for Aclaris Therapeutics Inc (ACRS). It details the company's current stock price, market capitalization, earnings per share, insider and institutional ownership, and a

Tone
Neutral 50/100
Event
Earnings
Published
12 Jun 2026 12:11
Source
Finviz
Stock Titan Direct company coverage

Aclaris Therapeutics (ACRS) director gains new RSUs and stock options

Aclaris Therapeutics director Maxine Gowen received 10,987 Restricted Stock Units and a stock option for 42,350 shares on June 4, 2026. On June 5, 2026, 11,580 RSUs vested, converting to common stock, leaving her with 33,334 direct common shares. This activity represents equity c

Tone
Neutral 50/100
Event
Market update
Published
09 Jun 2026 11:40
Source
Stock Titan
Stock Titan Direct company coverage

Aclaris (ACRS) director Andrew Schiff reports RSU vesting and new stock option grant

Aclaris Therapeutics director Andrew N. Schiff reported routine equity compensation, including the vesting of 11,580 restricted stock units (RSUs) which converted into common stock on June 5, 2026, increasing his direct holdings to 25,540 shares. He also received new grants on Ju

Tone
Neutral 50/100
Event
Market update
Published
08 Jun 2026 23:39
Source
Stock Titan
Insider Monkey Direct company coverage

Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On

Stifel has reiterated a Hold rating and increased the price target for Aclaris Therapeutics Inc. (ACRS) to $4, citing optimism about its multi-targeting approaches and immunology biology. The company is developing best-in-class compounds for immunological diseases, with positive

Tone
Neutral 50/100
Event
Analyst action
Published
07 Jun 2026 17:39
Source
Insider Monkey
MSN Direct company coverage

Aclaris Therapeutics maps busy pipeline calendar, plans phase 2 asthma trial for ATI-052

Aclaris Therapeutics is planning a busy period for its drug pipeline, highlighted by the upcoming phase 2 clinical trial for its investigational drug ATI-052 in asthma patients. This advancement indicates the company's focus on developing new treatments and expanding its therapeu

Tone
Positive 65/100
Event
Regulatory and legal
Published
07 Jun 2026 00:10
Source
MSN
Stock Titan Direct company coverage

Shareholders at Aclaris (NASDAQ: ACRS) back directors, executive pay and PwC

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) held its 2026 annual meeting where shareholders re-elected two directors, Anand Mehra, M.D. and Maxine Gowen, Ph.D., to serve until the 2029 annual meeting. They also approved the compensation of the company’s named executive officers on

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 12:10
Source
Stock Titan
Moomoo Direct company coverage

Aclaris Therapeutics Price Target Announced at $13.00/Share by LifeSci Capital

LifeSci Capital has set a price target of $13.00 per share for Aclaris Therapeutics (NASDAQ: ACRS). This announcement provides investors with an analyst's valuation perspective on the biopharmaceutical company. Investors may consider this price target in their evaluation of Aclar

Tone
Positive 68/100
Event
Analyst action
Published
03 Jun 2026 09:40
Source
Moomoo
GuruFocus Direct company coverage

ACRS Initiated Coverage by LifeSci Capital -- Rating 'Outperform'

LifeSci Capital initiated coverage on Aclaris Therapeutics (ACRS) with an 'Outperform' rating and a $13.00 price target, signaling a positive outlook for the biopharmaceutical company. Despite this, GuruFocus assesses ACRS as significantly overvalued with a GF Value™ of $0.46 aga

Tone
Negative 35/100
Event
Analyst action
Published
03 Jun 2026 03:40
Source
GuruFocus
Investing News Network Direct company coverage

Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its participation in the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 2:00 PM ET. CEO Dr. Neal Walker and other senior leaders will host a fireside chat, which will be webcast live and archived on the company'

Tone
Positive 60/100
Event
Market update
Published
28 May 2026 14:39
Source
Investing News Network